Price Discount Paves The Way For NICE To Clear GSK’s Revolade
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. drug cost watchdog NICE has cleared Glaxo’s Revolade and Alcon's Jetrea but rejected Lilly's Alimta as maintenance therapy in a subgroup of lung cancer patients.